Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial

Emmanouil Vrentzos; Ignatios Ikonomidis; George Pavlidis; Konstantinos Katogiannis; Emmanouil Korakas; Aikaterini Kountouri; Loukia Pliouta; Eleni Michalopoulou; Emilia Pelekanou; Dimitrios Boumpas; Vaia Lambadiari

doi:10.1186/s12933-024-02326-8

Cardiovascular Diabetology (Jul 2024)

Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial

Emmanouil Vrentzos,
Ignatios Ikonomidis,
George Pavlidis,
Konstantinos Katogiannis,
Emmanouil Korakas,
Aikaterini Kountouri,
Loukia Pliouta,
Eleni Michalopoulou,
Emilia Pelekanou,
Dimitrios Boumpas,
Vaia Lambadiari

Affiliations

Emmanouil Vrentzos: 4th Department of Internal Medicine, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens
Ignatios Ikonomidis: Laboratory of Preventive Cardiology and Echocardiography, 2nd Cardiology Department, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens
George Pavlidis: Laboratory of Preventive Cardiology and Echocardiography, 2nd Cardiology Department, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens
Konstantinos Katogiannis: Laboratory of Preventive Cardiology and Echocardiography, 2nd Cardiology Department, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens
Emmanouil Korakas: 2nd Department of Internal Medicine, Research Unit and Diabetes Center, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens
Aikaterini Kountouri: 2nd Department of Internal Medicine, Research Unit and Diabetes Center, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens
Loukia Pliouta: 2nd Department of Internal Medicine, Research Unit and Diabetes Center, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens
Eleni Michalopoulou: Laboratory of Preventive Cardiology and Echocardiography, 2nd Cardiology Department, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens
Emilia Pelekanou: 4th Department of Internal Medicine, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens
Dimitrios Boumpas: 4th Department of Internal Medicine, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens
Vaia Lambadiari: 2nd Department of Internal Medicine, Research Unit and Diabetes Center, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens

DOI: https://doi.org/10.1186/s12933-024-02326-8
Journal volume & issue: Vol. 23, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Backround Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD) has been associated with increased cardiovascular risk. The aim of this Randomized Double-blind clinical Trial was to evaluate the effects of coenzyme-Q10 supplementation in patients with MASLD in terms of endothelial, vascular and myocardial function. Methods Sixty patients with MASLD were randomized to receive daily 240 mg of coenzyme-Q10 or placebo. At baseline and at 6-months, the a)Perfused boundary region of sublingual vessels using the Sideview Darkfield imaging technique, b)pulse-wave-velocity, c)flow-mediated dilation of the brachial artery, d)left ventricular global longitudinal strain, e)coronary flow reserve of the left anterior descending coronary artery and f)controlled attenuation parameter for the quantification of liver steatosis were evaluated. Results Six months post-treatment, patients under coenzyme-Q10 showed reduced Perfused boundary region (2.18 ± 0.23vs.2.29 ± 0.18 μm), pulse-wave-velocity (9.5 ± 2vs.10.2 ± 2.3 m/s), controlled attenuation parameter (280.9 ± 33.4vs.304.8 ± 37.4dB/m), and increased flow-mediated dilation (6.1 ± 3.8vs.4.3 ± 2.8%), global longitudinal strain (-19.6 ± 1.6vs.-18.8 ± 1.9%) and coronary flow reserve (3.1 ± 0.4vs.2.8 ± 0.4) compared to baseline (p 0.05). In patients under coenzyme-Q10, the reduction in controlled attenuation parameter score was positively related to the reduction in Perfused boundary region and pulse wave velocity and reversely related to the increase in coronary flow reserve and flow-mediated dilation (p < 0.05 for all relations). Conclusions Six-month treatment with high-dose coenzyme-Q10 reduces liver steatosis and improves endothelial, vascular and left ventricle myocardial function in patients with MASLD, demonstrating significant improvements in micro- and macro-vasculature function. Trial Registration NCT05941910

Published in Cardiovascular Diabetology

ISSN: 1475-2840 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://cardiab.biomedcentral.com/

About the journal

Abstract

Keywords